Long-Term Outcome of XXXX Release.

@entity1 @entity1538 @entity4438 @entity3444 @entity1411 @entity479
BACKGROUND: @entity3444 is thought to be a self-limiting condition best treated by conservative measures, but despite this many @entity1 have a prolonged duration of symptoms and surgery may be indicated. @entity4438 release is reported to have a short-term success rate of up to 80%, but anecdotally this was not thought to represent our local experience. METHODS: An audit of long-term @entity1 -reported outcomes following open @entity1411 release was performed. A total of 30 @entity1 (33 feet) were identified over a 10-year period and case notes were reviewed. @entity1 were contacted by letter and invited to complete 2 validated @entity1 -reported outcome score questionnaires (Visual Analog Scale-Foot and Ankle [VAS-FA] and Manchester Oxford Foot Questionnaire [MOXFQ]). Responses were received from 24 @entity1 (26 feet). The average ages were 42.4 (range 24-61) for male and 46.2 (range 33-60) for female @entity1 , with a female/male ratio of 2.7:1. The average duration of treatment prior to operative intervention was 3.1 years (range 1-5). Preoperatively, our cohort underwent a range of conservative measures. All @entity1 were reviewed postoperatively, and average time from surgery to completion of questionnaires was 80 months (range 14-130). RESULTS: The outcomes were worse in @entity1 who had received preoperative @entity479 injections and this was found to be statistically significant. The mean MOXFQ score was 33.6    3.9 (0-64). Mean VAS-FA score was 57.8    4.9 (24-100). CONCLUSION: This study found a negative correlation between duration of follow-up and outcome, in both MOXFQ and VAS-FA, showing that @entity1 continued to improve many years postoperatively. The authors also found worse outcomes with preoperative @entity479 injections, better outcomes in older @entity1 , and a weak gender bias, suggesting results in @entity1 were better than those in @entity1 . A prolonged recovery period and generally poor outcomes leads the authors to suggest that @entity1538 release is of questionable clinical value and that @entity1 may improve in the natural course of the disease, in spite of surgery. LEVEL OF EVIDENCE: Level III, comparative study.
